Abbott Integrates Precision Oncology Tests into Flatiron's OncoEMR Platform
Event summary
- Abbott has integrated its Precision Oncology portfolio into Flatiron's OncoEMR platform, enabling digital test ordering and results viewing within the clinical workflow.
- The integration covers over 1,600 community cancer care centers and 4,700 providers in Flatiron's North American network.
- Available tests include Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard.
- The move aims to reduce administrative burden and accelerate treatment decisions for oncologists.
The big picture
This integration reflects the growing trend of healthcare providers leveraging digital platforms to streamline oncology care. By embedding Abbott's tests directly into Flatiron's OncoEMR, the partnership aims to reduce friction in treatment decision-making, addressing a key pain point in community oncology practices where most U.S. cancer care is delivered. The move also underscores the strategic importance of data-driven, personalized medicine in the oncology space.
What we're watching
- Adoption Pace
- How quickly community oncology practices will integrate Abbott's tests into their workflows.
- Competitive Response
- Whether other diagnostic companies will seek similar EMR integrations to remain competitive.
- Data Utilization
- The extent to which Flatiron's AI and machine learning capabilities will enhance the value of Abbott's test data.
Related topics